SCHEMBL14855041

SCHEMBL14855041

Cc1ccccc1COc1ccc(Nc2c(C#N)cnc3cc(OC4CCOC4)c(N)cc23)cc1Cl

nearest known ligand 0.49

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
▸ STK3 Q13188 3/20 0.49
▸ STK4 Q13043 3/20 0.49
▸ EGFR P00533 15/20 0.48
▸ ERBB2 P04626 14/20 0.48
▸ SRC P12931 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14855015 0.95 EGFR (0.51) STK3STK4EGFRERBB2SRC
SCHEMBL14854865 0.94 STK3 (0.49) STK3STK4EGFRERBB2SRC
SCHEMBL14854713 0.93 EGFR (0.54) STK3STK4EGFRERBB2SRC
SCHEMBL14854875 0.92 EGFR (0.53) STK3STK4EGFRERBB2SRC
SCHEMBL14854976 0.91 EGFR (0.54) STK3STK4EGFRERBB2
SCHEMBL14854756 0.90 EGFR (0.48) STK3STK4EGFRERBB2SRC
SCHEMBL14854934 0.90 STK3 (0.47) STK3STK4EGFRERBB2SRC
SCHEMBL14854618 0.90 EGFR (0.53) STK3STK4EGFRERBB2
SCHEMBL14855006 0.90 STK3 (0.61) STK3STK4EGFRERBB2SRC
SCHEMBL14855203 0.89 EGFR (0.46) STK3STK4EGFRERBB2SRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3222620-B1 CYANOQUINOLINE DERIVATIVES TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO LTD (CN) 2019-11-20 — — EP disclosed
EP-3222620-B1 CYANOQUINOLINE DERIVATIVES TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO LTD (CN) 2019-11-20 — — EP disclosed
US-10246443-B2 Cyanoquinoline derivatives TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) 2019-04-02 — — US disclosed
US-10246443-B2 Cyanoquinoline derivatives TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) 2019-04-02 — — US disclosed
EP-3222620-A1 CYANOQUINOLINE DERIVATIVES TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) 2017-09-27 — — EP disclosed
EP-3222620-A1 CYANOQUINOLINE DERIVATIVES TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) 2017-09-27 — — EP disclosed
US-20170226093-A1 CYANOQUINOLINE DERIVATIVES TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) 2017-08-10 — — US disclosed
US-20170226093-A1 CYANOQUINOLINE DERIVATIVES TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) 2017-08-10 — — US disclosed
US-20170226093-A1 CYANOQUINOLINE DERIVATIVES TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) 2017-08-10 — — US disclosed
US-9676724-B2 Cyanoquinoline derivatives TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) 2017-06-13 — — US disclosed
US-20160185728-A1 CYANOQUINOLINE DERIVATIVES TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) 2016-06-30 — — US disclosed
US-20160185728-A1 CYANOQUINOLINE DERIVATIVES TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) 2016-06-30 — — US disclosed
US-9187458-B2 Cyanoquinoline derivatives TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2015-11-17 — — US disclosed
US-9187458-B2 Cyanoquinoline derivatives TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2015-11-17 — — US disclosed
US-20130225579-A1 CYANOQUINOLINE DERIVATIVES TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2013-08-29 — — US disclosed
US-20130225579-A1 CYANOQUINOLINE DERIVATIVES TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2013-08-29 — — US disclosed
US-20130225579-A1 CYANOQUINOLINE DERIVATIVES TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2013-08-29 — — US disclosed
EP-2581372-A1 CYANOQUINOLINE DERIVATIVES Tianjin Hemay Bio-Tech Co., Ltd. (CN) 2013-04-17 — — EP disclosed
EP-2581372-A1 CYANOQUINOLINE DERIVATIVES Tianjin Hemay Bio-Tech Co., Ltd. (CN) 2013-04-17 — — EP disclosed
WO-2011153942-A1 CYANOQUINOLINE DERIVATIVES 天津和美生物技术有限公司 (CN) 2011-12-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10246443-B2 Cyanoquinoline derivatives CBR3, CYP3A4, CDK1 STK3 275/4885STK4 233/4885EGFR 4737/4885
US-20130225579-A1 CYANOQUINOLINE DERIVATIVES CBR3, CYP3A4, CDK1 STK3 275/4885STK4 233/4885EGFR 4737/4885
US-20160185728-A1 CYANOQUINOLINE DERIVATIVES CBR3, CYP3A4, CDK1 STK3 275/4885STK4 233/4885EGFR 4737/4885
US-20170226093-A1 CYANOQUINOLINE DERIVATIVES CBR3, CYP3A4, CDK1 STK3 275/4885STK4 233/4885EGFR 4737/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback